{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:29:10Z","timestamp":1790980150293,"version":"4.1.0"},"reference-count":34,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.3892\/ijo.2014.2303","type":"journal-article","created":{"date-parts":[[2014,2,14]],"date-time":"2014-02-14T10:59:54Z","timestamp":1392375594000},"page":"1394-1400","source":"Crossref","is-referenced-by-count":9,"title":["Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids"],"prefix":"10.3892","volume":"44","author":[{"given":"A.A.G.","family":"VAN TILBORG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.C.G.J.","family":"SWEEP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"GEURTS-MOESPOT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.M.","family":"WETZELS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.W.","family":"DE WAAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"WESTPHAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.F.A.G.","family":"MASSUGER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2014,2,14]]},"reference":[{"key":"key20180107182358_b1-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJM199512283332608","article-title":"Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis","volume":"333","author":"Folkman","year":"1995","journal-title":"N Engl J Med"},{"key":"key20180107182358_b2-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"key20180107182358_b3-ijo-44-04-1394","first-page":"H2091","article-title":"Molecular analysis of blood vessel formation and disease","volume":"273","author":"Carmeliet","year":"1997","journal-title":"Am J Physiol"},{"key":"key20180107182358_b4-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1055\/s-0038-1657610","article-title":"Angiogenesis: a dynamic balance of stimulators and inhibitors","volume":"78","author":"Iruela-Arispe","year":"1997","journal-title":"Thromb Haemost"},{"key":"key20180107182358_b5-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2141.2000.01864.x","article-title":"Current status of antiangiogenic factors","volume":"109","author":"Talks","year":"2000","journal-title":"Br J Haematol"},{"key":"key20180107182358_b6-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00001622-199601000-00011","article-title":"Mechanisms and therapeutic implications of angiogenesis","volume":"8","author":"Bicknell","year":"1996","journal-title":"Curr Opin Oncol"},{"key":"key20180107182358_b7-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0006-2952(00)00529-3","article-title":"Angiogenesis: regulators and clinical applications","volume":"61","author":"Liekens","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"key20180107182358_b8-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1523-1747.2000.00068.x","article-title":"Matrix metalloproteinases in human melanoma","volume":"115","author":"Hofmann","year":"2000","journal-title":"J Invest Dermatol"},{"key":"key20180107182358_b9-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1073\/pnas.040378497","article-title":"Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization","volume":"97","author":"Pozzi","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107182358_b10-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1126\/science.270.5241.1500","article-title":"Definition of two angiogenic pathways by distinct alpha v integrins","volume":"270","author":"Friedlander","year":"1995","journal-title":"Science"},{"key":"key20180107182358_b11-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.7512751","article-title":"Requirement of vascular integrin alpha v beta 3 for angiogenesis","volume":"264","author":"Brooks","year":"1994","journal-title":"Science"},{"key":"key20180107182358_b12-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0092-8674(94)90200-3","article-title":"Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma","volume":"79","author":"O\u2019Reilly","year":"1994","journal-title":"Cell"},{"key":"key20180107182358_b13-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O\u2019Reilly","year":"1997","journal-title":"Cell"},{"key":"key20180107182358_b14-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nm0295-149","article-title":"Dormancy of micro-metastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression","volume":"1","author":"Holmgren","year":"1995","journal-title":"Nat Med"},{"key":"key20180107182358_b15-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nm0696-689","article-title":"Angiostatin induces and sustains dormancy of human primary tumors in mice","volume":"2","author":"O\u2019Reilly","year":"1996","journal-title":"Nat Med"},{"key":"key20180107182358_b16-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"10868","DOI":"10.1073\/pnas.94.20.10868","article-title":"The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin","volume":"94","author":"Gately","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107182358_b17-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/(SICI)1097-0215(20000615)86:6<760::AID-IJC2>3.0.CO;2-4","article-title":"Angiostatin generation by human tumor cell lines: involvement of plasminogen activators","volume":"86","author":"Westphal","year":"2000","journal-title":"Int J Cancer"},{"key":"key20180107182358_b18-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.4049\/jimmunol.161.12.6845","article-title":"Matrix metalloproteinases generate angiostatin: effects on neovascularization","volume":"161","author":"Cornelius","year":"1998","journal-title":"J Immunol"},{"key":"key20180107182358_b19-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0092-8674(00)81926-1","article-title":"Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma","volume":"88","author":"Dong","year":"1997","journal-title":"Cell"},{"key":"key20180107182358_b20-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/sj.bjc.6692167","article-title":"Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen","volume":"81","author":"Heidtmann","year":"1999","journal-title":"Br J Cancer"},{"key":"key20180107182358_b21-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1515\/BC.2008.020","article-title":"Cathepsin V, but not cathepsins L, B and K, may release angiostatin-like fragments from plasminogen","volume":"389","author":"Puzer","year":"2008","journal-title":"Biol Chem"},{"key":"key20180107182358_b22-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1023\/A:1026525121027","article-title":"Angiostatin and angiostatin-related proteins","volume":"19","author":"Soff","year":"2000","journal-title":"Cancer Metastasis Rev"},{"key":"key20180107182358_b23-ijo-44-04-1394","first-page":"523","article-title":"Elevated levels of angiostatin in effusions from patients with malignant disease","volume":"11","author":"Rotenberg","year":"2004","journal-title":"Oncol Rep"},{"key":"key20180107182358_b24-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/172460089701200102","article-title":"A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols","volume":"12","author":"Grebenschikov","year":"1997","journal-title":"Int J Biol Markers"},{"key":"key20180107182358_b25-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/172460080001500210","article-title":"EORTC Receptor and Biomarker Study Group Report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts","volume":"15","author":"Span","year":"2000","journal-title":"Int J Biol Markers"},{"key":"key20180107182358_b26-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ygyno.2003.09.016","article-title":"Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression","volume":"92","author":"Murthi","year":"2004","journal-title":"Gynecol Oncol"},{"key":"key20180107182358_b27-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ygyno.2009.12.011","article-title":"Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer","volume":"117","author":"Drenberg","year":"2010","journal-title":"Gynecol Oncol"},{"key":"key20180107182358_b28-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.bjc.6690353","article-title":"Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer","volume":"80","author":"de Witte","year":"1999","journal-title":"Br J Cancer"},{"key":"key20180107182358_b29-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/sj.bjc.6690191","article-title":"Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients","volume":"79","author":"de Witte","year":"1999","journal-title":"Br J Cancer"},{"key":"key20180107182358_b30-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jnci\/94.2.116","article-title":"Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients","volume":"94","author":"Look","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"key20180107182358_b31-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/0008-5472.CAN-03-1820","article-title":"Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer","volume":"64","author":"Manders","year":"2004","journal-title":"Cancer Res"},{"key":"key20180107182358_b32-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1160\/TH03-07-0467","article-title":"The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer","volume":"91","author":"Manders","year":"2004","journal-title":"Thromb Haemost"},{"key":"key20180107182358_b33-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1471-2407-6-149","article-title":"Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators","volume":"6","author":"de Groot-Besseling","year":"2006","journal-title":"BMC Cancer"},{"key":"key20180107182358_b34-ijo-44-04-1394","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ijc.20400","article-title":"Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model","volume":"112","author":"de Groot-Besseling","year":"2004","journal-title":"Int J Cancer"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2014.2303\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T13:32:32Z","timestamp":1688995952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2014.2303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,14]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,2,14]]},"published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.3892\/ijo.2014.2303"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2014.2303","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,14]]}}}